2 Biotech Stocks That Are Dirt Cheap Right Now

During the first quarter, ended March 31, 2021, REGN’s revenue increased 38.3% year-over-year to $2.53 billion. Its operating income rose 58.9% from its year-ago value to $1.11 billion. The company’s non-GAAP net income increased 43.9% year-over-year to $1.11 billion, while its non-GAAP EPS came in at $9.89 for this quarter.

REGN is expected to generate 42.4%  revenue growth in the current year. Its EPS is estimated to increase 49.4% from its year-ago value to $47.01 in the current year. REGN’s stock has gained 20.1% year-to-date and 22.1% over the past three months.

In terms of forward Price/Sales, REGN is currently trading at 4.96x, which is 38.7% lower than the 8.09x industry average. Also, the stock’s 12.21x forward P/E  is also 49.7% lower than the 24.28x industry average.

REGN’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall B rating, which equates to Buy in our POWR Ratings system. REGN has an A grade for Growth and Value, and a B for Quality. Among the 497 stocks, it is ranked #4 in the Biotech industry. Click here to see more of REGN’s component grades (Momentum, Sentiment, and Stability).

Want More Great Investing Ideas?

9 "Must Own" Growth Stocks for 2021

7 SEVERELY Undervalued Stocks

Stock Market Outlook for 2nd Half of 2021

5 Ways to Beat the S&P 500


GILD shares were trading at $68.71 per share on Monday morning, up $0.49 (+0.72%). Year-to-date, GILD has gained 20.52%, versus a 17.43% rise in the benchmark S&P 500 index during the same period.

1 2 3
View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.